References
- Xu D, Jin G, Chai D, Zhou X, Gu W, Chong Y, et al. The development of CAR design for tumor CAR-T cell therapy. Oncotarget. 2018;9:13991–21. doi:https://doi.org/10.18632/oncotarget.24179.
- Zhao Z, Chen Y, Francisco NM, Zhang Y, Wu M. The application of CAR-T cell therapy in hematological malignancies: advantages and challenges. Acta Pharm Sin B. 2018;8:539–51. doi:https://doi.org/10.1016/j.apsb.2018.03.001.
- Maus MV, Grupp SA, Porter DL, June CH. Antibody-modified T cells: cARs take the front seat for hematologic malignancies. Blood. 2014;123:2625–35. doi:https://doi.org/10.1182/blood-2013-11-492231.
- Petersen CT, Krenciute G. Next generation CAR T cells for the immunotherapy of high-grade glioma. Front Oncol. 2019;9:69. doi:https://doi.org/10.3389/fonc.2019.00069.
- Park JH, Riviere I, Gonen M, Wang X, Senechal B, Curran KJ, Sauter C, Wang Y, Santomasso B, Mead E, et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med. 2018;378:449–59. doi:https://doi.org/10.1056/NEJMoa1709919.
- Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, Bader P, Verneris MR, Stefanski HE, Myers GD, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378:439–48. doi:https://doi.org/10.1056/NEJMoa1709866.
- Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377:2531–44. doi:https://doi.org/10.1056/NEJMoa1707447.
- Hartmann J, Schüßler‐Lenz M, Bondanza A, Buchholz CJ. Clinical development of CAR T cells-challenges and opportunities in translating innovative treatment concepts. EMBO Mol Med. 2017;9:1183–97. doi:https://doi.org/10.15252/emmm.201607485.
- Knochelmann HM, Smith AS, Dwyer CJ, Wyatt MM, Mehrotra S, Paulos CM. CAR T cells in solid tumors: blueprints for building effective therapies. Front Immunol. 2018;9:1740. doi:https://doi.org/10.3389/fimmu.2018.01740.
- Norelli M, Casucci M, Bonini C, Bondanza A. Clinical pharmacology of CAR-T cells: linking cellular pharmacodynamics to pharmacokinetics and antitumor effects. Biochim Biophys Acta. 2016;1865:90–100. doi:https://doi.org/10.1016/j.bbcan.2015.12.001.
- Stein AM, Grupp SA, Levine JE, Laetsch TW, Pulsipher MA, Boyer MW. Tisagenlecleucel model-based cellular kinetic analysis of chimeric antigen receptor-T cells. CPT Pharmacometrics Syst Pharmacol. 2019;8:285–95. doi:https://doi.org/10.1002/psp4.12388.
- Singh AP, Shin YG, Shah DK. Application of pharmacokinetic-pharmacodynamic modeling and simulation for antibody-drug conjugate development. Pharm Res. 2015;32:3508–25. doi:https://doi.org/10.1007/s11095-015-1626-1.
- Caruso HG, Hurton LV, Najjar A, Rushworth D, Ang S, Olivares S. Tuning sensitivity of CAR to EGFR density limits recognition of normal tissue while maintaining potent antitumor activity. Cancer Res. 2015;75:3505–18. doi:https://doi.org/10.1158/0008-5472.CAN-15-0139.
- Liu X, Jiang S, Fang C, Yang S, Olalere D, Pequignot EC, Cogdill AP, Li N, Ramones M, Granda B, et al. Affinity-tuned ErbB2 or EGFR chimeric antigen receptor T cells exhibit an increased therapeutic index against tumors in mice. Cancer Res. 2015;75:3596–607. doi:https://doi.org/10.1158/0008-5472.CAN-15-0159.
- Sta Maria NS, Khawli LA, Wolfe B, Zheng L, Lin SW, Pachipulusu V, Cohrs D, Manoli H Jr., Weist MR, Epstein AL, et al. Dose escalation study of 89Zr-labeled CAR-NK-92MI cells. Seattle (WA): World Molecular Imaging Congress; 2018.
- Friedman KM, Garrett TE, Evans JW, Horton HM, Latimer HJ, Seidel SL, Horvath CJ, Morgan RA. Effective targeting of multiple B-cell maturation antigen-expressing hematological malignances by anti-B-cell maturation antigen chimeric antigen receptor T cells. Hum Gene Ther. 2018;29:585–601. doi:https://doi.org/10.1089/hum.2018.001.
- Berahovich R, Xu S, Zhou H, Harto H, Xu Q, Garcia A. FLAG-tagged CD19-specific CAR-T cells eliminate CD19-bearing solid tumor cells in vitro and in vivo. Front Biosci (Landmark Ed). 2017;22:1644–54. doi:https://doi.org/10.2741/4563.
- Li S, Siriwon N, Zhang X, Yang S, Jin T, He F, Kim YJ, Mac J, Lu Z, Wang S, et al. Enhanced cancer immunotherapy by chimeric antigen receptor-modified T cells engineered to secrete checkpoint inhibitors. Clin Cancer Res. 2017;23:6982–92. doi:https://doi.org/10.1158/1078-0432.CCR-17-0867.
- Khot A, Matsueda S, Thomas VA, Koya RC, Shah DK. Measurement and quantitative characterization of whole-body pharmacokinetics of exogenously administered T cells in mice. J Pharmacol Exp Ther. 2019;368:503–13. doi:https://doi.org/10.1124/jpet.118.252858.
- Haddish-Berhane N, Shah DK, Ma D, Leal M, Gerber HP, Sapra P, Barton HA, Betts AM. On translation of antibody drug conjugates efficacy from mouse experimental tumors to the clinic: a PK/PD approach. J Pharmacokinet Pharmacodyn. 2013;40:557–71. doi:https://doi.org/10.1007/s10928-013-9329-x.
- Chapelin F, Gao S, Okada H, Weber TG, Messer K, Ahrens ET. Fluorine-19 nuclear magnetic resonance of chimeric antigen receptor T cell biodistribution in murine cancer model. Sci Rep. 2017;7:17748. doi:https://doi.org/10.1038/s41598-017-17669-4.
- Zhu H, Melder RJ, Baxter LT, Jain RK. Physiologically based kinetic model of effector cell biodistribution in mammals: implications for adoptive immunotherapy. Cancer Res. 1996;56:3771–81.
- Crispe IN, Dao T, Klugewitz K, Mehal WZ, Metz DP. The liver as a site of T-cell apoptosis: graveyard, or killing field? Immunol Rev. 2000;174:47–62. doi:https://doi.org/10.1034/j.1600-0528.2002.017412.x.
- Huang L, Soldevila G, Leeker M, Flavell R, Crispe IN. The liver eliminates T cells undergoing antigen-triggered apoptosis in vivo. Immunity. 1994;1:741–49. doi:https://doi.org/10.1016/S1074-7613(94)80016-2.
- Mehal WZ, Juedes AE, Crispe IN. Selective retention of activated CD8+ T cells by the normal liver. J Immunol. 1999;163:3202–10.
- Richard-Carpentier G, Kantarjian H, Jabbour E. Recent advances in adult acute lymphoblastic leukemia. Curr Hematol Malig Rep. 2019;14:106–18. doi:https://doi.org/10.1007/s11899-019-00503-1.
- Jusko WJ. Moving from basic toward systems pharmacodynamic models. J Pharm Sci. 2013;102:2930–40. doi:https://doi.org/10.1002/jps.23590.
- Cao Y, Cartwright EK, Silvestri G, Perelson AS. CD8+ lymphocyte control of SIV infection during antiretroviral therapy. PLoS Pathog. 2018;14:e1007350. doi:https://doi.org/10.1371/journal.ppat.1007350.
- Hardiansyah D, Ng CM. Quantitative systems pharmacology model of chimeric antigen receptor T-cell therapy. Clin Transl Sci. 2019. doi:https://doi.org/10.1111/cts.12636.
- Novel SGA. Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR. Nat Med. 2019 Sep;25(9):1408–1414. doi:https://doi.org/10.1038/s41591-019-0549-5. Epub 2019 Sep 2. PMID:31477906.
- Kershaw MH, Westwood JA, Parker LL, Wang G, Eshhar Z, Mavroukakis SA, White DE, Wunderlich JR, Canevari S, Rogers-Freezer L, et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res. 2006;12:6106–15. doi:https://doi.org/10.1158/1078-0432.CCR-06-1183.
- Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, Madduri D, Liedtke M, Rosenblatt J, Maus MV, Turka A, et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med. 2019;380:1726–37. doi:https://doi.org/10.1056/NEJMoa1817226.
- Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, Jäger U, Jaglowski S, Andreadis C, Westin JR, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380:45–56. doi:https://doi.org/10.1056/NEJMoa1804980.
- Mueller KT, Maude SL, Porter DL, Frey N, Wood P, Han X, Waldron E, Chakraborty A, Awasthi R, Levine BL, et al. Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia. Blood. 2017;130:2317–25. doi:https://doi.org/10.1182/blood-2017-06-786129.
- Mueller KT, Waldron E, Grupp SA, Levine JE, Laetsch TW, Pulsipher MA, Boyer MW, August KJ, Hamilton J, Awasthi R, et al. Clinical pharmacology of tisagenlecleucel in B-cell acute lymphoblastic leukemia. Clin Cancer Res. 2018;24:6175–84. doi:https://doi.org/10.1158/1078-0432.CCR-18-0758.
- Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, June CH. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med. 2011;3:95ra73. doi:https://doi.org/10.1126/scitranslmed.3002842.
- Turtle CJ, Hanafi LA, Berger C, Gooley TA, Cherian S, Hudecek M, Sommermeyer D, Melville K, Pender B, Budiarto TM, et al. CD19 CAR-T cells of defined CD4+: CD8+composition in adult B cell ALL patients. J Clin Invest. 2016;126:2123–38. doi:https://doi.org/10.1172/JCI85309.
- Milone MC, Bhoj VG. The pharmacology of T cell therapies. Mol Ther Methods Clin Dev. 2018;8:210–21. doi:https://doi.org/10.1016/j.omtm.2018.01.010.
- Shah DK, Betts AM. Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human. J Pharmacokinet Pharmacodyn. 2012;39:67–86. doi:https://doi.org/10.1007/s10928-011-9232-2.
- Watanabe K, Kuramitsu S, Posey AD Jr., June CH. Expanding the therapeutic window for CAR T cell therapy in solid tumors: the knowns and unknowns of CAR T cell biology. Front Immunol. 2018;9:2486. doi:https://doi.org/10.3389/fimmu.2018.02486.
- Chan PL, Jacqmin P, Lavielle M, McFadyen L, Weatherley B. The use of the SAEM algorithm in MONOLIX software for estimation of population pharmacokinetic-pharmacodynamic-viral dynamics parameters of maraviroc in asymptomatic HIV subjects. J Pharmacokinet Pharmacodyn. 2011;38:41–61. doi:https://doi.org/10.1007/s10928-010-9175-z.